Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic ...
Hosted on MSN1d
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapyAmgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...
GlobalData on MSN1d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialThe companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...
Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...
1d
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback